Evidence map›Paper›PMID 42728568›Full record

ArticleClinical pharmacology and therapeutics2026

Clinical Impact of Target-Mediated Drug Disposition of Small Molecules with Focus on Early Phase I Study Designs.

Francesca Tessaro, Neil John Parrott, Matthias B Wittwer, Franziska Schaedeli Stark, Andrés Olivares-Morales, Michael Derks, Stefan Sturm

Abstract read
In one paragraph

Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Francesca TessaroRoche Pharma Research and Early Development (pRED), Roche Innovation Center, Basel, Switzerland.ORCID https://orcid.org/0000-0001-8672-885X
Neil John ParrottRoche Pharma Research and Early Development (pRED), Roche Innovation Center, Basel, Switzerland.ORCID https://orcid.org/0000-0001-6821-7714
Matthias B WittwerRoche Pharma Research and Early Development (pRED), Roche Innovation Center, Basel, Switzerland.ORCID https://orcid.org/0000-0003-1359-4795
Franziska Schaedeli StarkRoche Pharma Research and Early Development (pRED), Roche Innovation Center, Basel, Switzerland.ORCID https://orcid.org/0009-0002-5692-3448
Andrés Olivares-MoralesRoche Pharma Research and Early Development (pRED), Roche Innovation Center, Basel, Switzerland.ORCID https://orcid.org/0000-0001-9959-0810
Michael DerksRoche Pharma Research and Early Development (pRED), Roche Innovation Center, Basel, Switzerland.ORCID https://orcid.org/0000-0002-4918-7828
Stefan SturmRoche Pharma Research and Early Development (pRED), Roche Innovation Center, Basel, Switzerland.ORCID https://orcid.org/0000-0003-4866-823X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42728568
PMCPMC13569714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.